TY - JOUR T1 - Predictive value of circulating NMR metabolic biomarkers for type 2 diabetes risk in the UK Biobank study JF - medRxiv DO - 10.1101/2021.10.11.21264833 SP - 2021.10.11.21264833 AU - Fiona Bragg AU - Eirini Trichia AU - Diego Aguilar-Ramirez AU - Jelena Bešević AU - Sarah Lewington AU - Jonathan Emberson Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/14/2021.10.11.21264833.abstract N2 - Background Effective targeted prevention of type 2 diabetes (T2D) depends on accurate prediction of disease risk. We assessed the role of metabolomic profiling in improving T2D risk prediction beyond conventional risk factors.Methods NMR-metabolomic profiling was undertaken on baseline plasma samples in 65,684 UK Biobank participants without diabetes and not taking lipid-lowering medication. Cox regression yielded adjusted hazard ratios for the associations of 143 individual metabolic biomarkers (including lipids, lipoproteins, fatty acids, amino acids, ketone bodies and other low molecular weight metabolic biomarkers) and 11 metabolic biomarker principal components (PCs) (accounting for 90% of total variance in individual biomarkers) with incident T2D. These 11 PCs were added to established models for T2D risk prediction, and measures of risk discrimination (c-statistic) and reclassification (continuous net reclassification improvement [NRI], integrated discrimination index [IDI]) were assessed.Findings During median 11.9 (IQR 11.1-12.6) years’ follow-up, 1719 participants developed T2D. After accounting for multiple testing, 118 metabolic biomarkers showed independent associations with T2D risk (false discovery rate controlled p<0.05), of which 103 persisted after additional adjustment for HbA1c. Overall, 10 metabolic biomarker PCs were independently associated with T2D. Addition of PCs to the established risk prediction model (including age, sex, parental history of diabetes, body mass index and HbA1c) improved T2D risk prediction as assessed by the c-statistic (increased from 0.802 [95% CI 0.791-0.812] to 0.830 [0.822-0.841]), continuous NRI (0.44 [0.38-0.49]), and relative (15.0% [10.5%-20.4%]) and absolute (1.5 [1.0-1.9]) IDI.Interpretation When added to conventional risk factors, circulating NMR-based metabolic biomarkers enhanced T2D risk prediction.Funding BHF, MRC, CRUKCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe British Heart Foundation, Medical Research Council and Cancer Research UK provide core funding to the Oxford CTSU. DAR acknowledges support from the BHF Centre of Research Excellence, Oxford (Grant code RE/13/1/30181). SL reports grants from the Medical Research Council (MRC) and research funding from the US Centers for Disease Control and Prevention Foundation (with support from Amgen) during the conduct of the study. JE reports grants from Boehringer Ingleheim, Regeneron and Astra Zeneca outside the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for the UK Biobank was obtained from the North West Multi-centre Research Ethics Committee (Ref: 11/NW/0382).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe underlying data are open access through application to the UK Biobank, and materials and methods will be made freely available through the UK Biobank as part of this project. ER -